Alzheimer’s – good and bad news

There is no still no scientific consensus on the causal mechanism of Alzheimer’s disease, or at least on the correct target for medicinal intervention – the four main contenders are:

(a) build-up of amyloid-beta fibrils

(b) build-up of tau protein tangles

(c) inflammation in the brain

(d) reaction to a virus infection

The Bad News: Last week the antibody drug “aducanumab” was withdrawn from clinical trials because of poor results – this was an anti-amyloid-beta drug. This follows other disappointing drugs aimed at amyloid-beta.

The Good News: However today there has been more positive news – a drug which has already been approved for clinical use against Hepatitis-D, called Lonafarnib, has been found to dramatically ameliorate the progress of dementia in a mouse model of the disease. The drug seems to block an enzyme (called farnesyltransferase) that facilitates the activity of the protein Rhes ultimately enhancing lysosome activity. Lysosomes are cellular waste-clearance systems that break down the toxic proteins, including tau. Research into this pathway and mechanism may open the door on further possible drugs.

Scientific American article

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s